HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

ghted that marketing authorisation for VELCADE has been granted, as it is the first major advance for patients with multiple myeloma in more than a decade, and marks the company's commitment to Oncology." said Ken Watters, European Medical Director, Ortho Biotech.

"The approval of VELCADE today brings renewed hope to thousands of European multiple myeloma patients and their families" said Eric Low, Executive Director, International Myeloma Foundation (UK). "The multiple myeloma advocacy community has campaigned tirelessly over the years for cutting edge treatments such as VELCADE to be made available to patients, this is a very proud day", he continued.

The findings of a pre-specified interim analysis from an ongoing phase III trial which compared VELCADE to dexamethasone in refractory multiple myeloma patients found a statistically significant improvement in time to disease progression the primary endpoint of the trial in patients receiving VELCADE compared to patients receiving high-dose dexamethasone. Patients in the control arm of the trial were given the opportunity to switch to VELCADE as soon as possible based on an interim analysis that found a statistically significant improvement in TTP in patients receiving VELCADE compared to patients receiving dexamethasone.

VELCADE has a generally predictable, manageable safety profile (with appropriate monitoring and if necessary, dose modification). VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. There are approximately 50 ongoing clinical trials (in Europe and the US) investigating the potential of VELCADE in all stages of multiple myeloma and other cancers.

A single licence has been granted to market VELCADE in the 15 member states of the EU, plus Norway and Iceland. In addition it will be available in the 10 accession countries.

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Ph
'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:11/24/2014)... The Holiday Inn Westbury - Long ... Children's Association to donate various items consisting of ... other such items.The Association's program is aimed toward helping ... in nursing homes, assisted living facilities and nursing homes. ... being of seniors throughout the Long Island area. The ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 ReAdmission ... and disease management services to health plans, hospitals, ... Essette’s Medical Management software suite. ReAdmission Solutions ... in a program to reduce patients' avoidable readmissions ... Health Management, Care Management, Utilization Management, and Appeals ...
(Date:11/23/2014)... 24, 2014 iFitDress.com, a well-known wedding dress ... evening gowns . They are now offered at deeply ... will last from now to Dec. 15. The main purpose ... All the company’s high quality items are ideal options for ... large sum of money. All its new mint cocktail dresses ...
(Date:11/23/2014)... 2014 Nearly 260 testosterone lawsuits ... deep vein thrombosis and other serious cardiovascular events ... litigation (MDL) underway in the Northern District of ... documents updated on November 17th by the U.S. ... filing of 259 lawsuits against the makers of ...
(Date:11/23/2014)... 23, 2014 To show thanks to new ... collection of white evening dresses for weddings. Customers ... 24/7. , iFitDress.com is a distinguished dress manufacturer, and it ... by worldwide customers for a very long time. The CEO ... a customer will be able to buy not only a ...
Breaking Medicine News(10 mins):Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2
(Date:11/24/2014)...  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced today that Sergio Traversa , chief executive ... "MAIN Event" Micro-Cap Growth Conference on Wednesday, December 3, ... Sunset Bel Air Hotel, which is located at 11461 ... . The presentation is scheduled for 8:30 ...
(Date:11/24/2014)... Calif. , Nov. 24, 2014  Rigel Pharmaceuticals, Inc. ... Gower is retiring from the board of directors and ... Raul Rodriguez , most recently serving as the company,s ... chief executive officer and join the board of directors.  ... since 2005, will become chairman. Mr. Gower is expected to ...
(Date:11/23/2014)... DAYTON, N.J. , Nov. 23, 2014  Aurobindo ... lot GESB14011-A of Gabapentin Capsules, USP 300 mg 100-count ... been found to contain some empty capsules. ... resulting in adverse health consequences that could range from ... withdrawal effect, or status epilepticus (long period seizures) that ...
Breaking Medicine Technology:Relmada Therapeutics To Present At LD MICRO Conference 2Rigel Announces Executive Management Changes 2Rigel Announces Executive Management Changes 3Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2
Cached News: